Justice Rofe has delivered a further supplementary decision in the dispute between Boehringer Ingelheim Animal Health USA Inc (Boehringer) and Zoetis Services LLC (Zoetis) in relation to three Zoetis vaccine patent applications. Her Honour has now held the last remaining valid claim to be invalid for failure to disclose the best method of performing the claimed invention.
We are delighted to announce that Pearce IP’s Founder and CEO, Naomi Pearce has been selected as a finalist for the 2024 IP Partner of the Year at the Lawyers Weekly Partner of the Year Awards.
29 APR 2024 | KR | Samil Pharmaceutical to Launch Samsung Bioepis’ Aflibercept in Korean Market from 1 May The Korean Biomedical Review has reported that Samil Pharmaceutical...
21 APR 2024 | US | Xbrane to Resubmit BLA for Ranibizumab Biosimilar following FDA CRL On 21 April 2024, Swedish biosimilar developer Xbrane announced that the FDA issued a...
The Full Federal Court has overturned the primary judge’s decision on construction and infringement (with respect to PinForce version 3) but upheld the primary judge’s decision on best method, in the latest case to be heard and decided in the long-running patent disputes between arch rivals in the field of carpark overstay detection.
12 APR 2024 | US | Six Regeneron Aflibercept US Patent Infringement Actions to be Centralized in West Virginia On 11 April 2024, the United States Judicial Panel on...
In a decision handed down on 2 April 2024 by the Full Federal Court, H.A.S Real Estate (H.A.S) has failed in its application for indemnity costs. The Court’s unanimous judgment by Justices Yates, Markovic and Kennett emphasises the critical importance of ensuring that an offer of compromise aligns with the orders and remedies which a party can receive through the court process.
05 APR 2024 | Samsung Bioepis Commences Phase 3 Trials for Keytruda® Biosimilar On 5 April 2024, Samsung Bioepis announced the commencement of Phase 3 clinical trials for SB27,...
28 MAR 2024 | US | Celltrion Launches US Pediatric High Concentration Adalimumab Biosimilar On 28 March 2024, the Korea IT Times reported the US launch of Celltrion’s pediatric...
On 8 March 2024, Justice Burley of the Federal Court issued the latest in a series of decisions relating to the patent-eligibility of Aristocrat’s electronic gaming machine (EGM) patents. Unfortunately it does not resolve the legal uncertainty created by the High Court’s split decision on the matter in 2022. What next?
Pearce IP’s Founder Naomi Pearce discusses this topic on prime time radio with ABC Law Report Host Damian Carrick, in light of the recent decision of the Federal Court in Allied Pumps Pty Ltd v LAA Industries Pty Ltd handed down in late November last year.
22 MAR 2024 | AU | Samsung Bioepis Seeks to Revoke Janssen’s Stelara® (ustekinumab) Patents in Australian Court On 22 March 2024, the first case management hearing was held...
MMD has been unsuccessful again in their infringement suit against Camco Engineering and also in their allegation that Camco contravened the Australian Consumer Law.
15 MAR 2024 | AU | November 2023 PBAC Public Summary Documents Feature Biopharma On 15 March 2024, the Australian Department of Health and Aged Care published the public summary...
On 8 March 2024, Justice Burley of the Federal Court issued the latest in a series of decisions relating to the patent-eligibility of Aristocrat’s electronic gaming machine (EGM) patents. Unfortunately it does not resolve the legal uncertainty created by the High Court’s split decision on the matter in 2022. What next?
As a Women Owned and led boutique IP firm, where pay parity is a given, Pearce IP celebrates International Women’s Day and the diversity, equity and inclusion of which we are...
As a Women Owned and led boutique IP firm, where pay parity is a given, Pearce IP celebrates International Women’s Day and the diversity, equity and inclusion of which we are...
As a Women Owned and led boutique IP firm, where pay parity is a given, Pearce IP celebrates International Women’s Day and the diversity, equity and inclusion of which we are...
On 5 March 2024, the Australian Patent Office (APO) issued its decision in the opposition filed by Clearview Towing Mirrors Pty Ltd in respect of Australian patent application AU2020281026 (Opposed Application). Clearview had opposed the grant of the Opposed Application on the grounds of inventive step, novelty, sufficiency, support and clarity.
As a Women Owned and led boutique IP firm, where pay parity is a given, Pearce IP celebrates International Women’s Day and the diversity, equity and inclusion of which we are...
As a Women Owned and led boutique IP firm, where pay parity is a given, Pearce IP celebrates International Women’s Day and the diversity, equity and inclusion of which we are...
9 MAR 2024 US | Samsung Bioepis Presents Interchangeability Updates for its Adalimumab and Ustekinumab Biosimilars at AAD On 9 March 2024, Samsung Bioepis presented two papers...
On 16 February 2024, IP Australia published that Ono Pharmaceutical Co. Ltd (Ono) was granted a patent term extension (PTE) in respect of its Australian Patent No. 2011203119 (Patent). This is the quiet conclusion to Ono’s dispute with the Patent Office relating to OPTIVO® (nivolumab) which culminated in an appeal court decision rejecting its previous application for PTE.
As a Women Owned and led boutique IP firm, where pay parity is a given, Pearce IP celebrates International Women’s Day and the diversity, equity and inclusion of which we are...
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.
